The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index; 13 of the 19 sources its claims cite were checked for support.
Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy
Open accessPublished version of a preprint
Abstract
Despite progress in clinical care for patients with coronavirus disease 2019 (COVID-19) 1 , population-wide interventions are still crucial to manage the pandemic, which has been aggravated by the emergence of new, highly transmissible variants. In this study, we combined the SIDARTHE model 2 , which predicts the spread of SARS-CoV-2 infections, with a new data-based model that projects new cases onto casualties and healthcare system costs. Based on the Italian case study, we outline several scenarios: mass vaccination campaigns with different paces, different transmission rates due to new variants and different enforced countermeasures, including the alternation of opening and closure phases. Our results demonstrate that non-pharmaceutical interventions (NPIs) have a higher effect on the epidemic evolution than vaccination alone, advocating for the need to keep NPIs in place during the first phase of the vaccination campaign. Our model predicts that, from April 2021 to January 2022, in a scenario with no vaccine rollout and weak NPIs ( $${\cal{R}}_0$$ R 0 = 1.27), as many as 298,000 deaths associated with COVID-19 could occur. However, fast vaccination rollouts could reduce mortality to as few as 51,000 deaths. Implementation of restrictive NPIs ( $${\cal{R}}_0$$ R 0 = 0.9) could reduce COVID-19 deaths to 30,000 without vaccinating the population and to 18,000 with a fast rollout of vaccines. We also show that, if intermittent open–close strategies are adopted, implementing a closing phase first could reduce deaths (from 47,000 to 27,000 with slow vaccine rollout) and healthcare system costs, without substantive aggravation of socioeconomic losses.
Overview
CoChat Summary
## TL;DR
The paper combines a compartmental epidemic model (SIDARTHE-V) with a data-based healthcare-cost model to evaluate how vaccination speed, SARS-CoV-2 variants, and non-pharmaceutical interventions (NPIs) affect COVID-19 outcomes in Italy. It concludes that NPIs have a larger impact than vaccination speed alone, especially early in the vaccination campaign.
## Key findings
- In the main scenarios, deaths from April 2021 to January 2022 ranged from 30,000 to 298,000 with no vaccination rollout, 20,000 to 91,000 with slow vaccination, 19,000 to 72,000 with medium vaccination, and 18,000 to 51,000 with fast vaccination.
- Under a scenario with weak restrictions and no vaccination, the model projects as many as 298,000 deaths; with restrictive NPIs (\(= 0.9\)), deaths could be reduced to 30,000 without vaccination and 18,000 with fast vaccination.
- If intermittent open–close strategies are used, starting with a closing phase instead of an opening phase could reduce deaths from 47,000 to 27,000 with slow vaccine rollout, without substantive worsening of socioeconomic losses.
- With medium vaccination speed and higher transmissibility from variants, the model predicts within 2 months a peak of almost 4,000 ICU beds needed and more than 700 daily deaths unless NPIs are strengthened.
## Methods
- The study combines two linked models: SIDARTHE-V, a compartmental model extended to include vaccination, and a data-driven model that maps predicted new cases to deaths, hospital occupancy, and ICU occupancy.
- Parameters for the epidemic model were fit to official Italian data from 24 February 2020 through 26 March 2021; the healthcare-cost model used second-wave data in a 110-day window ending 7 February 2021, plus age and demographic data from Italian public repositories.
- The authors simulated 20 scenarios from the combination of 4 vaccination schedules (absent, slow, medium, fast; reaching 0%, 47%, 64%, 90% immunized by January 2022) and 5 transmission/restriction profiles.
## Limitations
- The paper states that SIDARTHE-V is a mean-field compartmental model assuming homogeneous mixing, so it does not account for geographical heterogeneity; the text suggests more detailed spatial/social-network models could be used instead.
- The authors note they assumed vaccination is effective against SARS-CoV-2 variants, even though immune escape was a concern; this is a stated limitation.
- They also optimistically assumed protection against death and hospitalization starts 3 weeks after the first dose rather than after the second dose; this is stated as an assumption and may limit realism.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures












Verification
Claims the paper makes
9 Valid · 4 Not valid · 3 Not checked · 61 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In the meantime, vaccine rollout in the UK has enabled planning subsequent gradual release of NPIs38,39.”
§ Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy > Main
What the sources say
- Partly supportedcites [38] Lopez Bernal, J. et al. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England. Preprint at medRxiv https://doi.org/10.1101/2021.03.01.21252652 (2021). sourceExperimental — accuracy not yet measured
The Introduction describes the UK vaccine rollout and says effectiveness evidence is essential for decisions about non-pharmaceutical interventions. It does not say the rollout enabled planning for a gradual release of those interventions; the Discussion instead emphasizes maintaining precautions after vaccination. (LLM, conf=0.83)
- Not matchedcites [39] GOV.UK. Coronavirus (COVID‑19). https://www.gov.uk/coronavirus
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“the results of a clinical trial with the mRNA-1273 vaccine show that, despite a slight expected decline in titers of binding and neutralizing antibodies, mRNA-1273 has the potential to provide durable humoral immunity: as the natural infection, which produces variable antibody longevity and might induce robust memory B cell responses, also mRNA-1273 vaccine elicited primary CD4 type 1 helper T”
§ Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy > Methods > SIDARTHE-V compartmental model
What the sources say
- Partly supportedcites [40] Widge, A. T. et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N. Engl. J. Med. 384, 80–82 (2021). sourceExperimental — accuracy not yet measured
The article reports that binding and neutralizing antibodies remained elevated at day 119 and concludes that mRNA-1273 has the potential to provide durable humoral immunity. It also says that correlates of protection were not yet established; it does not show that protection persisted beyond day 119. The supplied article-body passages have no page numbers. (LLM, conf=0.88)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Multi-pronged countermeasures, including distancing, testing and tracing, are necessary to achieve a sustained reduction in infection cases20, even more so in light of the recent emergence of new SARS-CoV-2 variants21, such as B.1.1.7”
§ Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy > Main
What the sources say
- Supportedcites [20] Priesemann, V. et al. Calling for pan-European commitment for rapid and sustained reduction in SARS-CoV-2 infections. Lancet 397, 92–93 (2021). source
The paper’s strategy calls for firm action to reduce case numbers, followed by continued measures to keep them low. Its panel lists moderate contact reduction, testing, and contact tracing among those measures. (LLM, conf=0.92)
- Supportedcites [21] Priesemann, V. et al. An action plan for pan-European defence against new SARS-CoV-2 variants. Lancet 397, 469–470 (2021). source
Citation 21 is attached to the emergence of new SARS-CoV-2 variants, particularly B.1.1.7, rather than to the preceding claim about distancing, testing, and tracing, which carries citation 20. The opening section of the cited paper states that new variants are emerging and identifies B.1.1.7 among them. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In particular, the mild restrictions that kept around 0.9 with the original virus strain would keep it around 1.3 (at least) if the new variants increase transmissibility of at least 40–50%, as reported in the literature49–51.”
§ Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy > Methods > Our scenarios: different values of
What the sources say
- Partly supportedcites [49] Voltz, E. et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: insights from linking epidemiological and genetic data. Preprint at medRxiv https://doi.org/10.1101/2020.12.30.20249034 (2021). sourceExperimental — accuracy not yet measured
In 'Estimating reproduction numbers for VOC and non-VOC independently' (page unavailable), the paper reports mean reproduction numbers of 0.92 for non-VOC strains and 1.45 for B.1.1.7 during England’s second lockdown. The Abstract (page unavailable) estimates a 1.4–1.8 ratio, supporting the approximate numerical comparison. But the paper describes high levels of social distancing, not mild restrictions, and cautions against extrapolating its estimate to other transmission contexts or variants. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [50] Moore, J. P. Approaches for optimal use of different COVID-19 vaccines. Issues of viral variants and vaccine efficacy. JAMA https://doi.org/10.1001/jama.2021.3465 (2021). source
- Supportedcites [51] Davies, N. G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science https://doi.org/10.1126/science.abg3055 (2021). source
The Discussion estimates that B.1.1.7 had a 43–90% higher reproduction number than preexisting variants in England, assuming no change in generation interval. A 43% increase would take a reproduction number of 0.9 to about 1.3, consistent with the citing authors’ illustration. (LLM, conf=0.88)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Conversely, the basic reproduction number is the value of the parametric reproduction number at the first onset of the epidemic outbreak, and its value was estimated to range between 2.43 and 3.1 for SARS-CoV-2 in Italy43.”
§ Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy > Methods > SIDARTHE-V compartmental model
What the sources say
- Supportedcites [43] D’Arienzo, M. & Coniglio, A. Assessment of the SARS-CoV-2 basic reproduction number, R0, based on the early phase of COVID-19 outbreak in Italy. Biosaf. Health 2, 57–59 (2020). source
The Results and discussions section states that R₀ values associated with the early Italian outbreak may range from 2.43 to 3.10. The cited estimate matches the claim; the paper bases it on data from February 25 to March 12, 2020. (LLM, conf=0.94)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
29 more claims
Create a free account to see all 77 claims and every source verdict.
- It may state two separate claims as one. 32
- Probably not a substantial claim. 13
- The quote only partly states this claim. 3
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688 · cited 1×
“?̇?(t) = −S(t)(αI(t) + βD(t) + γA(t) + δR(t)) − φ(S(t)) (1) I(̇t) = S(t)(αI(t) + βD(t) + γA(t) + δR(t)) − (ε + ζ + λ)I(t) (2) ?̇?(t) = εI(t) − (η + ρ)D(t) (3) ?̇?(t) = ζI(t) − (θ + μ + κ)A(t) (4) ?̇?(t) = ηD(t) + θA(t) − (ν + ξ + τ1)R(t) (5) ?̇?(t) = μA(t) + νR(t) − (σ + τ2)T(t) (6)”
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656
Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period
Kissler, S. M., Tedijanto, C., Goldstein, E., Grad, Y. H., & Lipsitch, M. (2020) · Science · doi:10.1126/science.abb5793 · Cited by 2,611 · cited 1×
“The need to enforce new restrictions is likely to trigger intermittent containment measures, with the alternation of higher-ℛ and lower-ℛ phases 27,28 . higher-ℛ 0 lower-ℛ 0 In Open-Close strategies, closures are delayed and only enforced when the pressure on the healthcare system becomes…”
BackgroundEstimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2021) · Science · doi:10.1126/science.abg3055 · Cited by 2,581
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2020) · doi:10.1101/2020.12.24.20248822 · Cited by 2,557
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy
Giordano, G., Blanchini, F., Bruno, R., Colaneri, P., Di Filippo, A., Di Matteo, A., & Colaneri, M. (2020) · Nature Medicine · doi:10.1038/s41591-020-0883-7 · Cited by 1,740 · cited 1×
“The SIDARTHE-V compartmental model shown in Figure 1A extends the SIDARTHE model, first introduced by Giordano et al. 2 , by including the effect of vaccination.”
MethodSelf-citation
Cited by
Controlling the pandemic during the SARS-CoV-2 vaccination rollout
Viana, J., van Dorp, C. H., Nunes, A., Gomes, M. C., van Boven, M., Kretzschmar, M., Veldhoen, M., & Rozhnova, G. (2021) · Nature Communications · doi:10.1038/s41467-021-23938-8 · Cited by 149
Yang, J., Marziano, V., Deng, X., Guzzetta, G., Zhang, J., Trentini, F., Cai, J., Poletti, P., Zheng, W., Wang, W., et al. (2021) · Nature Human Behaviour · doi:10.1038/s41562-021-01155-z · Cited by 122
Ge, Y., Zhang, W., Wu, X., Ruktanonchai, C. W., Liu, H., Wang, J., Song, Y., Liu, M., Yan, W., Yang, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30897-1 · Cited by 111
Data-driven methods for present and future pandemics: Monitoring, modelling and managing
Álamo, T., Reina, D. G., Millán, P., Preciado, V. M., & Giordano, G. (2021) · Annual Reviews in Control · doi:10.1016/j.arcontrol.2021.05.003 · Cited by 78
“countermeasure is adopted, the better in terms of its efficacy and potential to save lives [86].”
BackgroundSelf-citationMesa, D. O., Hogan, A. B., Watson, O. J., Charles, G. D., Hauck, K., Ghani, A. C., & Winskill, P. (2022) · Communications Medicine · doi:10.1038/s43856-022-00075-x · Cited by 73
Metadata
- Authors
- Giordano, G., Colaneri, M., Di Filippo, A., Blanchini, F., Bolzern, P., De Nicolao, G., Sacchi, P., Colaneri, P., & Bruno, R.
- Affiliations
- University of Trento (IT)
- Policlinico San Matteo Fondazione (IT)
- University of Udine (IT)
- Politecnico di Milano (IT)
- Institute of Electronics, Computer and Telecommunication Engineering (IT)
- University of Pavia (IT)
- Corresponding author
- Giordano, Giulia
- ORCID
- Venue
- Nature Medicine
- Published
- 2021-04-16
- Volume
- 27
- Issue
- 6
- Pages
- 993-998
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC8205853
- OpenAlex
- W3155313092
- Cited by
- 192
- References
- 44
- Citations by year
- 2026: 2 · 2025: 13 · 2024: 15 · 2023: 36 · 2022: 79 · 2021: 46
- FWCI
- 16.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Medicine (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- arXiv (Cornell University) (submittedVersion)
- Iris (University of Trento) (submittedVersion, cc-by)
- Virtual Community of Pathological Anatomy (University of Castilla La Mancha) (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Institutional Research Information System (University of Udine) (submittedVersion, cc-by-nc-nd)
- arXiv (Cornell University)
- Funders
- European Commission (H2020 SC1, PRIN 2017, SC1-PHE-CORONAVIRUS-2020, H2020-SC1-PHE-CORONAVIRUS-2020-2-RTD, HORIZON2020, H2020, 101016233)
- Horizon 2020 Framework Programme (H2020-SC1-PHE CORONAVIRUS-2020-2-RTD, 101016233, H2020-SC1, 101016233, H2020-SC1-PHE CORONAVIRUS-2020-2-RTD)
- Topics
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Applied Mathematics › Mathematical and Theoretical Epidemiology and Ecology Models
- Keywords
- COVID-19 pandemic, SARS-CoV-2 variants, vaccine rollout, non-pharmaceutical interventions, epidemic modeling, COVID-19 mortality, basic reproduction number, Italy
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, Humans, Italy, Vaccination, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy. https://app.cochat.ai/papers/10.1038/s41591-021-01334-5
- The paper
- Giordano, G., Colaneri, M., Di Filippo, A., Blanchini, F., Bolzern, P., De Nicolao, G., Sacchi, P., Colaneri, P., & Bruno, R. (2021). Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy. Nature Medicine. https://doi.org/10.1038/s41591-021-01334-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.